Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of RC1416 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT07402551 is registered in ClinicalTrials.gov with Nanjing RegeneCore Biotech Co., Ltd. as lead sponsor.

NCT NCT07402551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07402551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of RC1416 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Lead sponsor
Nanjing RegeneCore Biotech Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
March 6, 2026
Completion date
August 30, 2028
Enrollment
180 (estimated)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe chronic obstructive pulmonary disease (copd)